MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
Live webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com. Webcast replays will be available for at least 30 days following the event.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
Todd Friedman
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.53 |
Daily Change: | 0.02 1.32 |
Daily Volume: | 7,127,971 |
Market Cap: | US$459.570M |
October 08, 2025 October 07, 2025 September 22, 2025 September 03, 2025 August 07, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load